Pharmaceutical manufacturer for Ursodeoxycholic acid

We specialize in premium Active Pharmaceutical Ingredients (APIs), Formulations, Innovative Drug Delivery Systems, and Specialty Chemicals using advanced technology with precision to adhere to global standards/specifications. Presently, we are recognized as one of the foremost global providers of Oncology/non-Oncology APIs, intermediates, and Formulations. Shilpa Medicare’s establishments have garnered significant regulatory endorsements from USFDA, EUGMP, TGA, PMDA, Cofepris, Anvisa, and KFDA, encompassing diverse regulatory approved manufacturing standards.

We are a Pharmaceutical Company aligned across two business verticals viz. Products and Services. Our Products business comprises manufacture and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both Domestic and International markets including the regulated markets.

Dipharma is a global Contract Development and Manufacturing Organisation (CDMO) and a leading manufacturer of Active Pharmaceutical Ingredients, with more than 500 employees, 4 cGMP plants and commercial offices in Italy, U.S.A. and China. We put our heart and soul into supporting our customers with a competitive and highly proactive approach, backed by 75 years of experience in safely handling hazardous chemical processes using state-of-the-art technologies. As a third-generation family-owned company, we have a long history of stability, commitment and financial solidity. We know how to deliver on creative innovation and we understand the critical importance of matching timelines, while operating in full respect of international regulations, Intellectual Property and third-party patents.

Formed through the fusion of Farmabios, Novasep, and PharmaZell, Axplora stands out as a principal manufacturer of active pharmaceutical ingredients (APIs), ensuring the timely and scalable delivery of high-quality compounds. With a collective proficiency and a diverse production capacity spanning 9 industrial facilities, incorporating specialized technologies such as Hazardous Chemistry, Chromatography, ADCs, Steroids, Continuous Processes, Lipids, and HPAPIs, Axplora provides dependable and flexible solutions: CDMO services for small molecule APIs and biopharmaceuticals to both innovators and generic API Products. We, at Axplora, are committed to unifying Farmabios, Novasep, and PharmaZell, establishing ourselves as a top-tier API manufacturer dedicated to serving the foremost patient-focused pharmaceutical and biotechnology enterprises, ensuring the reliable and sustainable production of premium active ingredients in adherence to the highest industry standards. Axplora's mission is centered on empowering pharmaceutical companies to enhance the development of vital medications, fostering a faster, safer, and more dependable approach to benefit patients worldwide. Leveraging our combined expertise and manufacturing facilities spread across nine sites in Europe and India, along with a research and development center in the USA, Axplora is positioned to offer comprehensive CDMO solutions.

Established in 1993, SUANFARMA is a business-to-business partner in the field of life sciences specializing in the formulation, manufacture, and marketing of components for the pharmaceutical, veterinary, and nutraceutical sectors. In SUANFARMA, we provide our CDMO capabilities for fermentation and chemical synthesis projects, delivering a comprehensive service with a proven track record, facilitating success in the formulation, expansion, production, and marketing of an API, whether it is innovative or generic

Mankind Pharma endeavors to support the community in promoting a healthy lifestyle by creating, formulating, marketing, and supplying cost-effective and easily accessible medications that meet critical medical requirements. Established in 1986, Mankind Pharma was formally incorporated as a company in 1991 and began operations as a fully-integrated pharmaceutical company in 1995. Presently, Mankind boasts a workforce of over 14,000 employees and is striving to achieve a revenue of $1 billion

Adare Pharma Solutions is a global technology-driven CDMO providing product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical industry. Adare’s specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions. With a proven history in drug delivery, Adare has developed and manufactured more than 65 products sold by customers in more than 100 countries globally.

PI Corporation is the one of top Japanese manufacturers of Active Pharmaceutical Ingredients (APIs)*, and intermediates to provide to pharmaceutical companies. We offer services in a wide range; focusing mainly in the CDMO (Contract Development and Manufacturing Organization) business of APIs and intermediates, we provide a rapid and accurate response to a variety of clients’ needs in synthetic route design, manufacturing process, pilot manufacturing /investigational medical manufacturing, and commercial manufacturing.

Sichuan Xieli Pharmaceutical Co., Ltd. was founded in 1980 with the development concept of "Xieli Tongchuang Health Cause". It mainly engages in the cultivation of ecological medicinal materials, the extraction of natural active ingredients from animals and plants, and the synthesis and research of their derivatives. It is based on the production of high value-added export products. There are mainly dozens of varieties, including rutin based cardiovascular and cerebrovascular drugs, plant flavonoids based capillary drugs, plant derived anti-tumor drugs, animal and plant extracts, and pharmaceutical intermediates.

Kimia Biosciences, established in 1993, specializes in the production of bulk drugs for various medical segments. With a strong focus on quality and advanced technologies, Kimia aims to achieve global recognition in the production of both APIs and FDFs, while maintaining ethical business practices. The state-of-the-art facilities at Village Bhondsi, Gurugram enable the production of a wide range of APIs. Additionally, Kimia plans to develop its own facilities for lifestyle segments, adhering to international regulatory standards, with the goal of delivering top-quality pharmaceutical products and support to both consumers and healthcare professionals.

ICE Pharma's primary focus is on the production of active pharmaceutical ingredients, with Ursodeoxycholic Acid (UDCA) being the key component, utilized in the treatment of liver conditions and gallstones. The company specializes in creating a variety of bile acid derivatives that serve as excipients, nutraceutical ingredients, cell culture media, and intermediates. Additionally, ICE Pharma offers contract manufacturing services for both liquid and solid finished dosage forms, catering to branded and generic products. Advent International, a leading global private equity investor, has owned ICE Pharma since October 2019.

Aspec Industry is the innovative energy system that allows companies to optimize and manage their consumption and the self-production of thermoelectric energy in an efficient and personalized manner. It was created to automatically and automatically meet the energy requirements of the users, thanks to the Aspec software algorithms, which are designed to choose the most convenient sources of supply based on technical/economic parameters.

Established in 2004 with a registered capital of 66 million yuan, Zhongshan Belling Biotechnology Co.,Ltd. is situated in the National Health Technology Park within the Torch Development Zone of Zhongshan City, Guangdong Province. Operating as a sino·foreign joint venture, Belling has been recognized as a National High Technology Enterprise in 2009, 2012, 2015 and 201, honored with the Technology R&D Center for Animal Pharmaceutical Ingredients award in 2013, successfully achieved UDCA GMP certification in 2015, accredited as the Guangdong Provincial Enterprise Technology Center in May 2018, and obtained the CEP certificate from EDQM in August 2019.

Symbio Generics India Private Limited, a specialized organization for manufacturing and promoting Active Pharmaceutical Ingredient (API) & intermediates, boasts cutting-edge facilities for research and development as well as production. The company's research and development center is located in Jigani (Bengaluru), while its manufacturing facilities are situated at Achutapuram, Vizag and VPL Chemical Pvt Ltd (a fully owned subsidiary) in the periphery of Bengaluru. Symbio has emerged as a strong contender in the API market.